AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...

The stock is also trading above its 50-day and 200-day moving averages. Image Source: Zacks Investment Research AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $214.00. The company’s shares opened today at $172.57.

In the last reported quarter, AbbVie reported an earnings surprise of 2.74%. Image Source: Zacks Investment Research Per our ...

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.